About Corona Remedies Limited
Data last updated: 14 July 2026
Corona Remedies Limited is a public limited company based in Daskroi, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 27 August 2004, the company has been in operation for over 22 years.
Registered with ROC Ahmedabad under CIN U24231GJ2004PLC044656. Listed.
Capital: an authorised share capital of ₹61.17 Cr and a paid-up capital of ₹61.16 Cr. It is led by directors including Ameetkumar Hiranyakumar Desai and Monica Hemal Kanuga.
Last AGM: 26 June 2025. Financial statements filed for year ended 31 March 2025. Office: Mondeal Business Park, Daskroi, Gujarat.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹1,403.18 Cr. The net worth stands at ₹746.86 Cr. Total assets are valued at ₹1,205.14 Cr.
The company has a workforce of approximately 4,625 employees as per the latest available data.
The company is associated with 1 brand - Corona Remedies. As per MCA filings, the company has open charges of ₹250 Cr and satisfied charges of ₹112.58 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website coronaremedies.com.
-
EmailLocked
-
TelephoneLocked
-
WebsiteLocked
-
Social Media
-
Registered AddressCorona House C – Mondeal Business Park, Near Gurudwara S. G. Highway, Daskroi, Gujarat, India – 380059
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Corona Remedies Limited
Corona Remedies Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24231GJ2004PLC044656, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231GJ2004PLC044656 | Current |
| U24231GJ2004PTC044656 | Previous |
| U24231GJ2004PLC044656 | Previous |
Associated Brands with Corona Remedies Limited
Corona Remedies Limited operates one associated brand: Corona Remedies. These brands represent Corona Remedies Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of pharmaceutical products focused on women's health, cardio-diabetology, pain management, and urology | coronaremedies.com |
Business Activity of Corona Remedies Limited
Corona Remedies Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Corona Remedies Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Corona Remedies Limited
Corona Remedies Limited is audited by Deloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Deloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Corona Remedies Limited
Corona Remedies Limited is currently managed by 8 directors, with 15 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ameetkumar Hiranyakumar Desai | Director | 22 Nov 2022 | 3 Years 7 Months | Current |
|
Monica Hemal Kanuga
Also directs:
Corona Remedies Limited
|
Director | 24 Oct 2024 | 1 Years 8 Months | Current |
|
Shirish Gundopant Belapure
Also directs:
Corona Remedies Limited, Bellapure Onco Phytoceuticals Llp, Jubilant Pharmova Limited and 4 more
|
Director | 04 Jan 2025 | 1 Years 6 Months | Current |
|
Nirav Kirtikumar Mehta
Also directs:
Corona Remedies Limited, Nkm Nextgen Llp
|
Managing Director | 30 May 2007 | 19 Years 1 Months | Current |
|
Ankur Kirtikumar Mehta
Also directs:
Corona Remedies Limited, Klnext Enterprise Llp
|
Managing Director | 27 Aug 2004 | 21 Years 10 Months | Current |
|
Kirtikumar Laxmidas Mehta
Also directs:
Corona Remedies Limited
|
Director | 27 Aug 2004 | 21 Years 10 Months | Current |
Financials of Corona Remedies Limited FY 2026 filings available
Corona Remedies Limited reported revenue of ₹1,403.18 Cr for FY 2026.
| Metrics | FY 2026 |
|---|---|
| Revenue from Operations | ₹1,403.18 Cr |
| Other Income | ₹10.65 Cr |
| Total Income | ₹1,413.83 Cr |
| Cost of Materials Consumed | ₹103.51 Cr |
| Purchases of Stock-in-Trade | ₹150.38 Cr |
| Changes in Inventories | ₹7.05 Cr |
| Employee Benefit Expense | ₹403.02 Cr |
| Finance Costs | ₹6.97 Cr |
| Depreciation & Amortisation | ₹37.87 Cr |
| Other Expenses | ₹445.78 Cr |
| Total Expenses | ₹1,154.58 Cr |
| Profit Before Exceptional Items & Tax | ₹259.25 Cr |
| Exceptional Items | -₹18.83 Cr |
| Profit Before Tax | ₹240.42 Cr |
| Total Tax Expense | ₹55.3 Cr |
| Net Profit | ₹185.12 Cr |
| attributable to Owners | ₹185.12 Cr |
| Other Comprehensive Income | ₹11 Lakh |
| Total Comprehensive Income | ₹185.23 Cr |
| EBITDA (computed) | ₹304.09 Cr |
| Basic EPS | ₹30.27 |
| Diluted EPS | ₹30.27 |
| Metrics | FY 2026 |
|---|---|
| Total Assets | ₹1,205.14 Cr |
| Non-current Assets | ₹856.83 Cr |
| Current Assets | ₹348.31 Cr |
| Property, Plant & Equipment | ₹291.14 Cr |
| Inventories | ₹125 Cr |
| Trade Receivables | ₹145.55 Cr |
| Cash & Equivalents | ₹1.83 Cr |
| Equity (Net Worth) | ₹746.86 Cr |
| Equity Share Capital | ₹61.16 Cr |
| Borrowings (Non-current) | ₹0 |
| Borrowings (Current) | ₹142.86 Cr |
| Total Debt (computed) | ₹142.86 Cr |
| Current Liabilities | ₹361.17 Cr |
| Total Liabilities | ₹458.28 Cr |
| Metrics | FY 2026 |
|---|---|
| Operating Cash Flow | ₹229.48 Cr |
| Investing Cash Flow | -₹256.15 Cr |
| Financing Cash Flow | ₹25.28 Cr |
| Capital Expenditure | ₹174.14 Cr |
| Free Cash Flow (computed) | ₹55.34 Cr |
| Dividends Paid | ₹0 |
| Net Change in Cash | -₹1.39 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 |
|---|---|---|---|
| Revenue from Operations | ₹353.09 Cr | ₹342.42 Cr | ₹361.13 Cr |
| Other Income | ₹4.11 Cr | ₹2.24 Cr | ₹2.27 Cr |
| Total Income | ₹357.2 Cr | ₹344.66 Cr | ₹363.4 Cr |
| Cost of Materials Consumed | ₹27.73 Cr | ₹24.82 Cr | ₹25.9 Cr |
| Purchases of Stock-in-Trade | ₹46.34 Cr | ₹41.15 Cr | ₹28.11 Cr |
| Changes in Inventories | -₹7.83 Cr | -₹5.7 Cr | ₹14.64 Cr |
| Employee Benefit Expense | ₹106.63 Cr | ₹95.94 Cr | ₹103 Cr |
| Finance Costs | ₹1.38 Cr | ₹1.66 Cr | ₹1.93 Cr |
| Depreciation & Amortisation | ₹10.29 Cr | ₹9.45 Cr | ₹9.2 Cr |
| Other Expenses | ₹118.2 Cr | ₹103.05 Cr | ₹111.01 Cr |
| Total Expenses | ₹302.74 Cr | ₹270.37 Cr | ₹293.79 Cr |
| Profit Before Exceptional Items & Tax | ₹54.46 Cr | ₹74.29 Cr | ₹69.61 Cr |
| Exceptional Items | ₹28 Lakh | -₹19.08 Cr | ₹0 |
| Profit Before Tax | ₹54.74 Cr | ₹55.21 Cr | ₹69.61 Cr |
| Total Tax Expense | ₹9.41 Cr | ₹13.94 Cr | ₹17.46 Cr |
| Net Profit | ₹45.33 Cr | ₹41.27 Cr | ₹52.32 Cr |
| attributable to Owners | ₹45.33 Cr | ₹41.27 Cr | ₹52.32 Cr |
| Other Comprehensive Income | ₹67 Lakh | -₹6 Lakh | ₹31 Lakh |
| Total Comprehensive Income | ₹46 Cr | ₹41.21 Cr | ₹52.63 Cr |
| EBITDA (computed) | ₹66.13 Cr | ₹85.4 Cr | ₹80.74 Cr |
| Basic EPS | ₹7.41 | ₹6.75 | ₹8.55 |
| Diluted EPS | ₹7.41 | ₹6.75 | ₹8.55 |
| Metrics | FY 2026 |
|---|---|
| Revenue from Operations | ₹1,403.18 Cr |
| Other Income | ₹10.65 Cr |
| Total Income | ₹1,413.83 Cr |
| Cost of Materials Consumed | ₹103.51 Cr |
| Purchases of Stock-in-Trade | ₹150.38 Cr |
| Changes in Inventories | ₹7.05 Cr |
| Employee Benefit Expense | ₹403.02 Cr |
| Finance Costs | ₹6.97 Cr |
| Depreciation & Amortisation | ₹37.87 Cr |
| Other Expenses | ₹445.78 Cr |
| Total Expenses | ₹1,154.58 Cr |
| Profit Before Exceptional Items & Tax | ₹259.25 Cr |
| Exceptional Items | -₹19.1 Cr |
| Profit Before Tax | ₹240.15 Cr |
| Total Tax Expense | ₹55.3 Cr |
| Net Profit | ₹184.85 Cr |
| Other Comprehensive Income | ₹11 Lakh |
| Total Comprehensive Income | ₹184.96 Cr |
| EBITDA (computed) | ₹304.09 Cr |
| Basic EPS | ₹30.22 |
| Diluted EPS | ₹30.22 |
| Metrics | FY 2026 |
|---|---|
| Total Assets | ₹1,204.25 Cr |
| Non-current Assets | ₹855.94 Cr |
| Current Assets | ₹348.31 Cr |
| Property, Plant & Equipment | ₹291.14 Cr |
| Inventories | ₹125 Cr |
| Trade Receivables | ₹145.55 Cr |
| Cash & Equivalents | ₹1.83 Cr |
| Equity (Net Worth) | ₹745.97 Cr |
| Equity Share Capital | ₹61.16 Cr |
| Borrowings (Non-current) | ₹0 |
| Borrowings (Current) | ₹142.86 Cr |
| Total Debt (computed) | ₹142.86 Cr |
| Current Liabilities | ₹361.17 Cr |
| Total Liabilities | ₹458.28 Cr |
| Metrics | FY 2026 |
|---|---|
| Operating Cash Flow | ₹229.48 Cr |
| Investing Cash Flow | -₹256.15 Cr |
| Financing Cash Flow | ₹25.28 Cr |
| Capital Expenditure | ₹174.14 Cr |
| Free Cash Flow (computed) | ₹55.34 Cr |
| Dividends Paid | ₹44.71 Cr |
| Net Change in Cash | -₹1.39 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 |
|---|---|---|---|
| Revenue from Operations | ₹353.09 Cr | ₹342.42 Cr | ₹361.13 Cr |
| Other Income | ₹4.11 Cr | ₹2.24 Cr | ₹2.27 Cr |
| Total Income | ₹357.2 Cr | ₹344.66 Cr | ₹363.4 Cr |
| Cost of Materials Consumed | ₹27.73 Cr | ₹24.82 Cr | ₹25.9 Cr |
| Purchases of Stock-in-Trade | ₹46.34 Cr | ₹41.15 Cr | ₹28.11 Cr |
| Changes in Inventories | -₹7.83 Cr | -₹5.7 Cr | ₹14.64 Cr |
| Employee Benefit Expense | ₹106.63 Cr | ₹95.94 Cr | ₹103 Cr |
| Finance Costs | ₹1.38 Cr | ₹1.66 Cr | ₹1.93 Cr |
| Depreciation & Amortisation | ₹10.29 Cr | ₹9.45 Cr | ₹9.2 Cr |
| Other Expenses | ₹118.2 Cr | ₹103.05 Cr | ₹111.01 Cr |
| Total Expenses | ₹302.74 Cr | ₹270.37 Cr | ₹293.79 Cr |
| Profit Before Exceptional Items & Tax | ₹54.46 Cr | ₹74.29 Cr | ₹69.61 Cr |
| Exceptional Items | ₹0 | -₹19.1 Cr | ₹0 |
| Profit Before Tax | ₹54.46 Cr | ₹55.19 Cr | ₹69.61 Cr |
| Total Tax Expense | ₹9.41 Cr | ₹13.94 Cr | ₹17.46 Cr |
| Net Profit | ₹45.05 Cr | ₹41.25 Cr | ₹52.15 Cr |
| Other Comprehensive Income | ₹67 Lakh | -₹6 Lakh | ₹31 Lakh |
| Total Comprehensive Income | ₹45.72 Cr | ₹41.19 Cr | ₹52.46 Cr |
| EBITDA (computed) | ₹66.13 Cr | ₹85.4 Cr | ₹80.74 Cr |
| Basic EPS | ₹7.37 | ₹6.74 | ₹8.53 |
| Diluted EPS | ₹7.37 | ₹6.74 | ₹8.53 |
Board & Governance of Corona Remedies Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Corona Remedies Limited has 8 directors - 4 independent and 3 executive. The board is chaired by Kirtikumar Laxmidas Mehta.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Kirtikumar Laxmidas Mehta | Non-Executive - Non Independent Director · Chairperson | 2004-08-27 | 1 |
| Niravkumar Kirtikumar Mehta | Executive Director · CEO-MD | 2007-05-30 | 1 |
| Ankur Kirtikumar Mehta | Executive Director · MD | 2004-08-27 | 1 |
| Viral Bhupendrabhai Sitwala | Executive Director | 2010-01-01 | 1 |
| Ameetkumar Hiranyakumar Desai | Non-Executive - Independent Director | 2022-11-22 | 5 |
| Monica Hemal Kanuga | Non-Executive - Independent Director | 2024-10-24 | 1 |
| Shirish Gundopant Belapure | Non-Executive - Independent Director | 2025-01-04 | 4 |
| Bhaskar Vemban Iyer | Non-Executive - Independent Director | 2025-01-04 | 3 |
| Committee | Members |
|---|---|
| Audit Committee | Ameetkumar Hiranyakumar Desai (Chairperson), Ankur Kirtikumar Mehta, Monica Hemal Kanuga |
| Nomination and remuneration committee | Bhaskar Vemban Iyer (Chairperson), Kirtikumar Laxmidas Mehta, Ameetkumar Hiranyakumar Desai |
| Stakeholders Relationship Committee | Monica Hemal Kanuga (Chairperson), Niravkumar Kirtikumar Mehta, Bhaskar Vemban Iyer |
| Risk Management Committee | Shirish Gundopant Belapure (Chairperson), Viral Bhupendrabhai Sitwala, Bhaskar Vemban Iyer |
| Corporate Social Responsibility Committee | Kirtikumar Laxmidas Mehta (Chairperson), Ankur Kirtikumar Mehta, Ameetkumar Hiranyakumar Desai |
Charges & Borrowings of Corona Remedies Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Dec 2023 | Others | ₹50 Cr | Open |
| 07 Jul 2023 | Citi Bank N.A. | ₹200 Cr | Open |
| 28 Aug 2019 | Others | ₹32.75 Lakh | Satisfied |
| 22 Aug 2019 | Others | ₹60.61 Lakh | Satisfied |
| 02 Feb 2019 | Hdfc Bank Limited | ₹50 Cr | Satisfied |
Total charge records: 14 View all charges
Employees and EPFO Compliance at Corona Remedies Limited
View historical data on people associated with Corona Remedies Limited, including employment history and EPFO contributions.
Employee and EPFO history for Corona Remedies Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Corona Remedies Limited
GST registrations and filing compliance for Corona Remedies Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Corona Remedies Limited
Credit ratings, litigation, and regulatory alerts for Corona Remedies Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Corona Remedies Limited
MSME payment history for Corona Remedies Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Corona Remedies Limited
Corporate group structure for Corona Remedies Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Corona Remedies Limited
MCA filings and documents for Corona Remedies Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Corona Remedies Limited
Recent News on Corona Remedies Limited
Frequently Asked Questions about Corona Remedies Limited
Corona Remedies Limited is an active public limited company in the pharma sector based in Daskroi, Gujarat, India. It was incorporated on 27 August 2004 (22+ years old) and is registered under CIN L24231GJ2004PLC044656. The company has 4,625 employees.
Corona Remedies Limited reported revenue of ₹1,403.18 Cr for FY 2026 based on consolidated NSE filings.
The current directors of Corona Remedies Limited are:
- Ameetkumar Hiranyakumar Desai - Director
- Monica Hemal Kanuga - Director
- Shirish Gundopant Belapure - Director
- Nirav Kirtikumar Mehta - Managing Director
- Ankur Kirtikumar Mehta - Managing Director
- Kirtikumar Laxmidas Mehta - Director
- Bhaskar Vemban Iyer - Director
- Viral Bhupendrabhai Sitwala - Whole-Time Director
The primary industry of Corona Remedies Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes, Corona Remedies Limited is a listed company.
Corona Remedies Limited can be reached at the registered office: Corona House C – Mondeal Business Park, Near Gurudwara S. G. Highway, Daskroi, Gujarat, India – 380059, or through the website coronaremedies.com.